Exercise and GLP-1 RA on Insulin Secretion

Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes

The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.

The effects of endurance exercise alone or in addition to treatment with glucagon-like- peptide receptor agonists on insulin secretory capacity, will be determined in patients with type 2 diabetes.

Included patients will be randomized to either 12 weeks of endurance exercise training 3 times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of endurance exercise training 3 times a week. Insulin secretory capacity will be determined by hyperglycemic clamp method before and after.

Inclusion Criteria:

• Diagnosed with type 2 diabetes
• BMI 28-35
• Moderately preserved insulin secretory capacity (determined by glucagon test)

Exclusion Criteria:

• Insulin treatment
• Hypertension grade 3
• Heart disease
• Medical history with pancreatitis
• Diagnosed with neuropathy
• Excessive alcohol consumption
• Any condition that would interfere with the protocol.